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Abstract
Hematopoiesis requires the spatiotemporal organization of regulatory factors to successfully orchestrate diverse lineage
specificity from stem and progenitor cells. Med12 is a regulatory component of the large Mediator complex that enables
contact between the general RNA polymerase II transcriptional machinery and enhancer bound regulatory factors. We have
identified a new zebrafish med12 allele, syr, with a single missense mutation causing a valine to aspartic acid change at
position 1046. Syr shows defects in hematopoiesis, which predominantly affect the myeloid lineage. Syr has identified a
hematopoietic cell-specific requirement for Med12, suggesting a new role for this transcriptional regulator.
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Introduction
Effective hematopoiesis requires the organized differentiation of
multipotent stem cells and progenitor cells into a spectrum of
specialized cell types. Achieving this diverse outcome is dependent
on the precise timing of initiation of multiple individual cell-
restricted gene expression programs. It is important, therefore, to
understand how combinatorial inputs from the general RNA
polymerase (RNAP) II transcriptional machinery and lineage-
specific transcription factors align to specify the development of
diverse cell types. Mediator is an essential component of the
transcriptional machinery that regulates the activity of RNAP II
by transmitting information from transcription factors bound to
upstream promoter and enhancer elements to the general
transcription initiation factors bound to the core promoter. It
was originally described in yeast as a coactivator of RNAP II, but
is evolutionarily conserved, with an equivalent complex present in
mammals [1,2]. Mammalian Mediator comprises up to 30
proteins and exists in two major forms. The core complex,
Mediator, contains 25 subunits plus Med26 and is generally
required as a strong coactivator of transcription. The other form,
Med12-Mediator (or CDK8-Mediator), contains the same 25
subunits plus the Med12 module, consisting of Med12, Med13,
CDK8 and Cyclin C. Med12-Mediator is capable of regulating
transcription both positively and negatively, depending on context.
The Med12 module has been shown to act as a molecular switch
that shuts down activated transcription upon binding to Mediator
by blocking reinitiation by RNAP II [3]. Furthermore, Med12 but
not Med13 is essential for activating CDK8 kinase and can lead to
transcriptional repression independently of CDK8 kinase. How-
ever, Med12 also interacts with the activation domains of SOX9
and Rta, supporting its role in transcriptional activation [4,5]. The
hedgehog signaling effector, Gli3, targets Med12 through its
activation domain and has been proposed to act by reversing the
transcriptional repression caused by the Med12 module [6]. In
addition, Med12 has been shown to interact with the histone
methyl transferase, G9A, which is responsible for the transcrip-
tionally repressive H3K9 methylation mark [7].
The molecular mechanisms of Mediator regulatory function are
not well understood. However, it appears that individual subunits
of the complex interact specifically with different activators or
repressors to selectively fine-tune the regulation of specific
signaling pathways. For example, Med1 interacts with nuclear
receptors, Med23 is required for the MAP kinase pathway [8],
myc interacts with CDK8 [9] and Med15 is required for TGFb
signaling [10]. Med12 contains a leucine-rich domain, a leucine-
and serine-rich (LS) domain, a PQL (proline-, glutamine-, leucine-
rich) domain and an OPA (glutamine-rich) domain. SOX9, Gli3
and b-catenin all interact with the PQL domain of Med12 [4,6,11]
and Rta interacts with two Med12 fragments that share the N-
terminal region of the PQL domain in common [5]. In vivo
evidence supporting the importance of Med12 in these pathways is
provided by several animal models. Med12 null mice, which are
arrested at E7.5, show a loss of canonical Wnt/b-Catenin
signaling, while Med12 hypomorphic mice also display neural
tube closure defects and cardiac malformations [12]. In zebrafish,
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are embryonic lethal and predicted to be null mutants. kohtalo,
which contains a premature stop codon in Med12, has defects in
brain, neural crest and kidney development [13]. Analysis of two
other med12 alleles, trapped and motionless, with predicted trunca-
tions in the N-terminal third of the protein, has implicated Med12
coactivation of sox9 as the basis of the neural crest defects and
revealed other neuronal defects [14,15]. Another allele, shiri,
demonstrates a role for Med12 in the regulation of Sox32, Sox4b,
Hnf-4 and Her5 in endodermal development [16]. Aside from the
involvement of the PQL domain in protein-protein interactions,
the functional domains of Med12 remain largely uncharacterized.
It is interesting, however, that a 12 bp insertion in the C-terminal
OPA domain in humans is associated with mental retardation,
schizophrenia and hypothyroidism, suggesting an important
function for this domain [17,18,19]. While cardiovascular defects
have been observed in all the above Med12-deficient animal
models, their hematopoietic development has not been examined.
Hematopoiesis in zebrafish, as in mammals, occurs in two stages,
primitive and definitive. During primitive hematopoiesis, progen-
itors develop from about 12 hours post fertilization (hpf) at two
anatomically separate sites: rostrally, primitive myeloid cells
expressing pu.1 appear while caudally, erythroid–specified cells
expressing gata1 develop [20]. These cells start circulating at about
26 hpf and at this time, markers of definitive hematopoiesis such as
c-myb and runx1 are expressed in the trunk of the embryo just ventral
to the dorsal aorta [21]. This region is equivalent to the AGM
(aorta–gonad–mesonephros region) in mammals and cells produced
here have been shown to migrate to the ventral tail of the embryo,
forming an intermediate site which seeds hematopoietic cells to the
definitive hematopoietic organs, the thymus and kidney [22]. This
caudal hematopoietic tissue appears to be equivalent to the
mammalian fetal liver. Myeloperoxidase (Mpx) can be detected
from about 18 hpf in the intermediate cell mass (ICM, ventral trunk
and tail), before the initiation of definitive hematopoiesis, suggesting
that some granulocytes may develop during the primitive phase
[23]. We have identified mature granulocytes at 2 dpf by electron
microscopy [24]. Interestingly, the mutant spadetail, which lacks
trunk mesoderm due to a mutation in T-box gene 16 (tbx16),
contains detectable granulocytes, providing evidence that they may
arise from the rostral site of hematopoiesis as well as the ICM [20].
Congenital myeloid failure occurs either in isolation, or as part
of global hematopoietic failure, or as one element of a multiple
system congenital defect [25]. While some of the causative genetic
defects have been discovered [26,27], many are still unknown. In
an endeavor to identify new genetic requirements of myelopoiesis,
a forward genetic screen was undertaken in zebrafish for mutants
defective in myeloid cell development, and syrah (syr), was
identified as a recessive mutant with reduced myeloperoxidase
(mpx) expression. A missense mutation in the LS region of Med12
underpins the syr phenotype.
Results
Isolation and identification of syr mutation
Syr was identified for its reduced expression of mpx at 44 hpf.
The mutation is recessive and embryonic lethal, with homozygous
embryos surviving for about 5 dpf. A 10 cM genome scan placed
syr on chromosome 14 in a region dense with markers, which
enabled rapid narrowing of the critical genetic interval containing
Figure 1. Positional cloning of syr gene, Med12. (A) Genetic interval showing four gene candidates: Med12, (1) Met RNA synthetase
(LOC566565), (2) heatshock protein 4 (hspa4) and (3) glucosamine-6-P deaminase (gnpda1); (B) Sequencing of V1046D with mutated amino acid in
red; asterisk marks the T.A transversion; (C) Schematic of Med12 protein with syr mutation shown by red line. Previously identified mutations are
indicated by green lines; positions of N1763S and 4 amino acid deletion sequence variations are indicated; conservation of V1046 in Med12 across
species (Accession numbers: XP_003209328, XP_521116, CAG08329, CAC44632, XP_002727624, CAM24448, XP_001088424, NP_005111,
XP_001915364, XP_538072, XP_695002).
doi:10.1371/journal.pone.0023845.g001
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2,785 mutant embryos narrowed the genetic interval to 4 genes,
using SNP and RFLP markers that were developed in the interval.
One of these genes, med12, was a likely candidate on the basis that
another mutant of this gene displayed a combination of
phenotypes similar to syr. cDNAs were cloned and sequenced
from syr mutant and wild-type embryos, and a T.A transversion
resulting in a V1046D amino acid change in Med12 was identified
in the mutant (Fig. 1B). This residue, which lies in the LS domain
in the middle of the protein, is conserved in all vertebrate
sequences available and is, therefore, a likely candidate for the
causative mutation (Fig. 1C). The T.A mutation was not present
in the somatic DNA of the ENU-treated founder from which syr
was derived, confirming it was ENU-induced. In addition, two
sequence variations, an asparagine to serine change at amino acid
1763 (N1763S) and a 12 bp deletion at nucleotide 6374 (del)
resulting in a 4 amino-acid deletion in the C-terminal OPA
domain of Med12, were identified (Fig. 1C). Both of these occur in
poorly conserved regions of the protein. Because the mutant is
recessive, and heterozygotes do not differ from wild-type in their
phenotype, syr is expected to be a loss-of-function mutation rather
than a gain-of-function or constitutively active mutation.
A V1046D mutation in med12 underpins syr
An amino acid change in the sequence of a highly conserved
residue is probable but not conclusive as the cause of a phenotype.
Based on knowledge of the phenotype, a series of genetic proofs
were therefore undertaken to establish causality. Knockdown of
Med12 mRNA in wild-type embryos by microinjection of a syr
antisense morpholino oligonucleotide phenocopied the mutant in
both neural and hematopoietic phenotypes (Fig. 2A). Conversely,
overexpression of Med12 mRNA was able to robustly rescue both
the neural and hematopoietic (decreased mpx expression) pheno-
types of syr (Fig. 2B–C). There was no apparent overexpression
phenotype in injected wild-type embryos. In addition to the valine
to aspartic acid change at position 1046, two other sequence
variations were identified: an asparagine to serine change at
position 1763, and a 12 bp deletion resulting in a 4 amino acid
deletion in the C-terminal OPA domain (Fig. 1C). Microinjection
of Med12 mRNA containing both these sequence variations (SV),
but not the V1046D mutation, fully rescued syr (Fig. 2D),
demonstrating that these variations do not contribute to syr.
Conversely, Med12 mRNA containing either the V1046D
mutation alone or in conjunction with the two sequence variations
(SVM) was not able to rescue, confirming that V1046D is the
underlying mutation in syr. Lastly, a complementation test with
another Med12 mutant allele, tpd
t25870 [13], showed non-
complementation of the syr phenotype, again confirming Med12
as the gene containing the lesion responsible for syr (Fig. 2E).
Med12 is required for myelopoiesis
Whole mount in situ hybridisation (WISH) shows reduction of
mpx expression in syr is evident as early as 28 hpf, indicating either
a decrease in transcription of myeloperoxidase or a decrease in
cells expressing this marker. Concomitant decreases in the
expression of several other myelomonocytic markers at 28–33
hpf including lyz, npsn1, lcp1, spi1, c-fms and mmp13 suggest the
decrease in mpx is likely due to a reduction in the number of
Figure 2. Genetic validation of V1046D mutant Med12
underpinning syr phenotype. (A) Phenocopy of syr by injection of
Med12 morpholino; phenotype (PT), genotype (GT) and morpholino
(MO) injection are indicated. The upper panel are bright field photos
and the lower panels show WT and syr on a Tg(mpx:EGFP) background
for enumeration of mpx expressing cells. (B) Rescue of syr neural
phenotype with wild-type Med12; phenotype (PT), genotype (GT) and
mRNA injected. (C) Rescue of myeloid defect in syr by overexpression of
wild-type Med12 mRNA; genotype (GT) and mRNA injected are
indicated. (D) Rescue of syr with wild-type (WT) Med12 and Med12
containing the two sequence variations, N1763S and a 12 bp deletion
but not the V1046D mutation (SV). Rescue does not occur with injection
of V1046D Med12 (MUT) or Med12 containing the two sequence
variations in addition to the V1046D mutation (SVM). (E) Non-
complementation of syr with trapped (tpd). Rescued mutants were
PCR genotype confirmed.
doi:10.1371/journal.pone.0023845.g002
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expression of markers identifying the other hematopoietic lineages,
were examined. Lack of rag1 expression at 3.5 dpf suggests that T
lymphocyte development may be defective (Fig. 3O–P). To
distinguish between loss of thymocytes and loss of the thymus
itself, foxn1 expression was examined (Fig. 3Q–R). Thymic
epithelial cells marked by expression of foxn1 were evident in
both wild-type and mutant, suggesting the thymus is intact and
that the absence of rag1 reflects a defect or delay in thymocyte
development. The thrombocyte marker, cd41, is also absent at 3.5
dpf in syr (Fig. 3S–T) pointing to an additional defect in the
development of this lineage. These data from later time points are
presented with the caveat, however, that since syr is embryonic
lethal, not surviving past day 5, altered expression of these later
markers could be attributed to general biological deterioration of
the embryo.
Erythropoiesis is not affected in syr
In contrast to myeloid markers, expression of embryonic globins
at 48 hpf is normal in syr, as is expression of two earlier erythroid
markers, gata1 and znfl2 at 18–20 somites. This indicates that
within hematopoiesis the myeloid lineage is more affected by the
syr defect than the erythroid lineage (Fig. 4A–D). Transverse
sections through the trunk of wild-type and syr embryos at 3 dpf
demonstrate the presence of erythrocytes (Fig. 4E–F). Although
erythrocytes are seen to circulate in syr, there are variable
circulatory defects, with a generally later onset of circulation,
development of edema over the yolk and eventual cessation of
circulation by 3 dpf. To determine if this resulted from defects in
vascular development, syr was crossed with homozygous
Tg(fli1a:EGFP)
y1 fish, generating mutants with fluorescent vascu-
lature. Confocal microscopy shows the head vasculature is
markedly reduced and disrupted in syr compared to wild-type,
especially in the common cardinal vein (ccv), which is difficult to
see in syr and the aortic arches (aa) which are anteriorly bowed
compared to wild-type (Fig. 4G–H). This is likely secondary to the
gross abnormalities in brain morphogenesis that are noticeable
from ,28 hpf, rather than abnormality in vascular development
per se. Vasculature in the tail shows formation of the major caudal
artery (ca) and vein (cv) as well as the dorsal longitudinal
anastomotic vessel (dlav) and intersomitic vessels (isv) in syr with
few gross morphological differences compared to wild-type,
suggesting that the cardiovascular phenotype in syr is not due to
gross disruption of the vasculature (Fig. 4I–J).
Med12 is required later in hematopoietic development
Assessment of hematopoietic development by WISH shows that
in syr early hematopoietic progenitors are specified normally,
indicated by scl, pu.1, ikaros and gata1 expression comparable to
wild-type at 17–19 hpf (Fig. 5A–D). The presence of runx1 at 30
hpf in both mutant and wild-type indicates that definitive
hematopoiesis is initiated (Fig. 5E–F). However, expression of scl
is no longer evident by 3 dpf suggesting a potential defect in
hematopoietic stem cell (HSC) migration from the dorsal aorta
and/or failure in caudal hematopoietic tissue development
(Fig. 5G–H).
In order to determine if loss of function in syr was due to a loss of
Med12 cleared by mRNA surveillance processing, Med12
expression was analyzed. WISH showed that Med12 was strongly
expressed in the anterior of mutant as well as wild-type embryos
(Fig. 5I–L) indicating syr has impaired Med12 function rather than
a loss of transcripts. The insets of Fig. 5I–J, show Med12
localization in the ICM hematopoietic region.
Residual neutrophils in Med12-deficient embryos can
migrate
A basic function of neutrophils is to migrate to the site of a
wound. In order to examine whether the few neutrophils present in
syr were capable of this behavior, a classic tail snip assay [24] was
used. Syr was crossed onto a Tg(mpx:EGFP) background to facilitate
visualization of leukocytes. 8 h post transection, migration of mpx
Figure 3. Hematopoiesis defects in syr. Myelomonocytic markers
were examined at 23–28 hpf by WISH (A–N); T lymphocyte and thymic
epithelium markers were examined at 3.5 dpf in syr and wt (O–R);
staining of the thrombocyte marker, cd41 at 3 dpf (S–T). WISH embryos
are representative of $4 (median=21) examples.
doi:10.1371/journal.pone.0023845.g003
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syr embryos indicating that residual neutrophils can migrate in syr
(Fig. 6).
Discussion
A forwardgeneticscreen hasidentifiedMed12 as critical for early
myelopoiesis in zebrafish. Although several mutant alleles of Med12
have been identified, none have described the predominantly
myeloid defects in hematopoiesis seen in the new syr allele. We have
not determined the mechanism whereby these defects occur nor
whether these hematopoiesis phenotypic features are direct or
indirectconsequencesofMed12deficiency.Primitive hematopoiesis
can take place normally in syr but correct lineage specification does
not occur and definitive hematopoiesis is compromised.
The mutation underpinning syr is a single T.A transversion
resulting in a valine to aspartic acid change in the LS domain of
Med12. This component of Mediator is highly conserved among
vertebrates. The human sequence is 97% identical to mouse and
75% identical to zebrafish predicted sequences. Although the C-
terminal PQL domain has been shown to be necessary for protein-
protein interaction, the function of other Med12 domains remains
largely unexplored. The zebrafish Med12 alleles studied previously
are either nonsense mutations or mutations causing downstream
nonsense mutations predicting severely truncated proteins. In
contrast, syr is a missense mutation where Med12 transcript
expression by WISH is largely indistinguishable between wild-type
and mutant. This provides some insight into the role of the LS
domain in Med12 function, since alteration of a single amino acid
in this domain disrupts protein function.
Studies of Med12 function have identified important roles in
neural, ear and endoderm development [12,13,14,15,16] as
well as hepatocyte differentiation [16]. Interaction of med1/
trap220 with gata1 has been reported, providing a precedent for
the involvement of Mediator in hematopoiesis [28]. More
recently, Med12/13 but not CycC or Cdk8 components of the
Med12-module have been shown to be essential for transactiva-
tion in cell culture by the GATA/RUNX factors, Serpent and
Lozenge, in Drosophila. Furthermore, while the Med12 module
controls proliferation of the crystal cell lineage, only Med12/13
regulate its differentiation [29] suggesting a specific role for
Med12 rather than a more generalized role as a component of
Med. In addition, large scale microarray analysis of gene
expression in the normal physiological state in human and
mouse tissues and cell lines shows highest expression of Med12
in mouse B and T lymphocytes, lymph node and thymus (.3-
fold above the median), and was above the median in bone
marrow but below the median in spleen [29,30]. This suggests
that the absence of thymocytes in syr may not be due to
deterioration of the embryo at this stage (3–5dpf) and that
Med12 could have a role in lymphopoiesis. Because syr embryos
do not survive long enough for B cell development to occur, this
pathway has not been investigated. The human results were
similar, with high expression in lymphocytes, peripheral blood
CD14+ monocytes and CD34+ BM cells. These results are
consistent with the expression we have seen in the zebrafish
ICM (data not shown). There is also evidence for differential
Med12 protein expression from the Swedish human protein
database [31] and Human Protein Atlas (www.proteinatlas.org/
ENSG00000184634; accessed 6/23/11). Immunohistochemis-
try data from one antibody shows greatest expression in bone
marrow, placenta and Purkinje cells while a stronger antibody
was less discriminating, showing expression in most tissues.
These data are consistent with the hypothesis that Med12 may
Figure 4. Erythropoiesis proceeds normally in syr. Examination of early erythroid markers at 17–19 hpf in syr (A–B); staining of embryonic
globin in wt and syr at 48 hpf (C–D); transverse sections of WT and syr embryos at 3 dpf, counterstained with hematoxylin and eosin; notochord (N)
and neutrophils (arrowheads) are indicated (E–F); syr crossed with Tg(fli1a:EGFP) shows close to normal vasculature in both head (G–H) and tail (I–J).
Heads are dorsal view with anterior to left, WT on the left (G) and syr on the right (H); aa (aortic arches) and ccv (common cardinal vein) are indicated.
Tails are lateral view, anterior to left and ca (caudal artery), cv (caudal vein), dlav (dorsal longitudinal anastomotic vessel) and isv (intersomitic vessels)
are indicated.
doi:10.1371/journal.pone.0023845.g004
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provide evidence for a role of Med12 in hematopoiesis
independent of the syr mutant.
There is in vitro evidence to suggest that myc interacts with
CDK8 [9] and because of the role of myc in hematopoiesis and
disease it has been considered a potential target for Med12
[32,33]. We considered the syr phenotype could be due in part to
defective transcription of myc, but though expression of mych, a
member of the myc family in zebrafish that is expressed in a
subpopulation of neutrophils [34], appears to be decreased in syr
compared to wild-type, this is most likely due to fewer leukocytes
in syr rather than an actual decrease in mych transcripts. Similarly,
microinjection of mych did not rescue syr (data not shown). This in
vivo observation confirms the in vitro dissection of the myc-Mediator
interaction, which indicates that CDK8 but not Med12 or Med13
are able to interact with myc [35].
There is growing evidence that loss of ubiquitous proteins such
as hspa9b, ribosomal protein Rps19, TIF1U and cpsf1 can
selectively affect hematopoiesis [36,37,38,39]. The overarching
function of Mediator is to orchestrate spatiotemporal localization
of regulatory factors so that proteins bound to the enhancer can be
brought into contact with transcriptional machinery at the
promoter [1,2,40]. Recently, Mediator and cohesin have been
shown to be localized uniquely at active, cell type-specific genes,
forming a set of DNA loops specific to each cell type [41]. We
therefore propose that the missense mutation in Med12 could
potentially affect direct or indirect interaction with required
hematopoietic-specific factors or disrupt the DNA loop signature
of myeloid genes to generate the hematopoietic defects seen in syr.
Materials and Methods
Ethics Statement
Fish were housed in the Ludwig Institute for Cancer Research
Aquarium using standard husbandry practices. All experiments
were approved by the Ludwig Institute for Cancer Research or
Walter and Eliza Hall Institute Animal Ethics Committees (AEC
Approval IDs 2007.012 and 2009.027).
Zebrafish lines
Zebrafish strains used were: AB*, syrah (syr
gl10, a novel mutant
isolated in our ethylnitrosourea mutagenesis screen [42] for its lack
of myeloperoxidase [mpx] expression), Tg(fli1a:EGFP)
y1 [43] and
Tg(mpx:EGFP)
i114 [44]. Zebrafish gene, protein, and mutant
naming follow the nomenclature conventions recommended by
www.zfin.org.
Microinjections
Fertilized 1- to 2-cell embryos were microinjected with 1 to
2 nL synthetic mRNA (520 ng/mLi nH 2O), Med12 splice site
Figure 5. Stages of hematopoiesis in syr. Early hematopoietic
markers are expressed normally in syr at 17–19 hpf (A–D) (note that
Figs. 4A and 5C are the same; Fig. 4A/5C is included here for
completeness). Definitive hematopoiesis is initiated in syr indicated by
runx1 expression at 28 hpf (E–F). Caudal hematopoietic tissue fails to
develop in syr indicated by lack of scl1 expression at 3 dpf (G–H). Med12
is expressed in WT and syr with insets showing staining in the
hematopoietic ICM region (I–J); dorsal view of staining (K–L). Unless
otherwise stated, WISH embryos are representative of $10, and #46,
examples.
doi:10.1371/journal.pone.0023845.g005
Figure 6. Residual neutrophils can migrate in syr. Top panels: WT
prior to tail snip (uncut) and 8 h post transection (cut); Bottom panels:
Syr prior to tail snip (uncut) and 8 h post transection (cut). Neutrophils
at the wound margin have been circled.
doi:10.1371/journal.pone.0023845.g006
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Tools, Philomath, OR); or control MO (see Table S1 for
sequence), (130 mmol/L in H2O; Gene_Tools) traced where
appropriate by mixing 1:1 with 5% rhodamine-dextran (in
0.2 mol/L KCl).
Positional cloning, oligonucleotides and constructs
A 10 cM scan was performed against a panel of SSLP (simple
sequence length polymorphism) markers, which placed syr on
chromosome 14. The region was subsequently narrowed using
RFLP markers and SNP analysis. Table S1 lists oligonucleotide
sequences used. Sequence data have been deposited in GenBank
(Accession number: JN226108). Med12 constructs were derived
from pCS2+ or pBluescript II KS+ (Thermo Fisher Scientific,
Australia) by standard cloning techniques and linearized with NotI
for in vitro transcription of capped mRNA using the mMESSAGE
mMACHINE kit (Ambion, Austin, TX). Internal AflII and MluI
restriction endonuclease sites were used to isolate the V1046D
mutation from the C-terminal N1763S and12 bp deletion
mutations and vice versa using a region swapping approach (see
Table S1 for cloning primers). All constructs were validated by
sequencing.
Gene expression analysis
Whole mount in situ hybridization (WISH) was performed using
standard techniques [20]. In vitro transcribed digoxigenin- or
fluorescein-labeled antisense cd41, c-fms, foxn1, gata1, hbae3, ikzfl1,
lcp1, lyz, mmp13, mpx, npsn1, rag1, runx1, scl1, spi1 and znfl2
riboprobes were detected with 4-nitroblue tetrazolium/5-bromo-
4-chloro-3-indolyl phosphate.
Imaging
Low-power images were collected using a Nikon SMZ1500 or
Nikon 90i fluorescence microscope equipped with a DXM1200c
camera and Nis-Elements AR software (Nikon, Tokyo, Japan), and
high-power images with a Nikon Optiphot-2 microscope with a
Zeiss AxioCam MRc5 digital camera and AxioVision AC (Release
4.5) software (Zeiss, Welwyn Garden City, United Kingdom).
Images were imported into Adobe Photoshop CS2 9.0.2 or
Illustrator CS2 12.0.1 (Adobe Systems, Mountain View, CA) for
orientation and figure preparation.
Tail snip assay
Tails of 6 to 8 embryonic zebrafish were transected at 49 hpf as
described [24]. 8 h post-transection, embryos were examined for
localization of EGFP-marked leukocytes.
Genotyping
syr embryos were recognized as a Mendelian proportion and by
their characteristic syndrome of small eyes, disruption of neural
region, lack of ventricle inflation, and thinner yolk extension.
Younger syr embryos were PCR-genotyped at the closely linked
simple sequence length polymorphism (SSLP) marker z7495
(oligonucleotides, Table S1; 10 mL reactions; Phusion polymerase
[New England Biolabs, Ipswich, MA] with supplied GC buffer;
92uC, 2 minutes followed by 40 cycles at 92uC, 60uC, and 72uC
for 30, 30, and 60 seconds, respectively; PCR products were
separated by 2% agarose gel electrophoresis or sequenced
following PCR.
Supporting Information
Table S1 Sequences of oligonucleotides used in this
study.
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